At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,031 enrolled
Drug / intervention
FF/GW642444 Inhalation Powder +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 3 clinical trial evaluating FF/GW642444 Inhalation Powder, FF Inhalation Powder, and 2 other interventions for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 1,031 participants across 132 sites in 10 countries.
Detailed Summary
The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesChile, Estonia, Germany, Japan, Mexico, Philippines, Poland, Russia, South Korea, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedJan 2010
Primary CompletionFeb 2011
Study CompletionApr 2011
TodayJul 2026
First PostedJan 22, 2010
Enrollment StartOct 5, 2009
Primary CompletionFeb 1, 2011
Study CompletionApr 14, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.4 years ago
Interventions
FF/GW642444 Inhalation Powderdrug
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
FF Inhalation Powderdrug
Inhaled Corticosteroid (ICS)
GW642444 Inhalation Powderdrug
Long Acting Beta Agonist(LABA)
Placebodrug
Placebo